Scheduled Maintenance

Our site will be undergoing scheduled maintenance from 08:30 AM EST to 9:30 AM EST. During this window the site will remain available, though you may experience a brief interruption of service. Thank you for your patience.
×

NCT07255664
Clinical Trial Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07255664
Title A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC (ProbeTILity)
Acronym ProbeTILity
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Curacell Holding AB
Indications
colorectal cancer
prostate cancer
Therapies
Aldesleukin + Cyclophosphamide + Mesna
Pembrolizumab
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Krankenhaus Nordwest RECRUITING Frankfurt 60488 Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field